Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A new NIH transition notice appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record itself remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-20T22:09:28.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T22:21:13.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, replacing the previous detailed content. Sponsor-related materials and links to study documents have been removed.
    Difference
    18%
    Check dated 2026-09-23T00:10:28.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.6 to v3.7.0 on the page, signaling a new document revision. It appears to be a metadata/versioning update rather than a substantive change to study content.
    Difference
    0.0%
    Check dated 2026-09-15T23:04:30.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This indicates a new version of the page rendering, applied as a maintenance or QA update without altering study details or user interactions.
    Difference
    0.0%
    Check dated 2026-09-01T19:42:04.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    A new line '2017 ( U.S. NIH Grant/Contract )' was added under Other Study ID Numbers, providing an additional funding identifier for the trial. This addition supplies extra context about funding but does not modify the study's primary data.
    Difference
    0.0%
    Check dated 2026-08-25T20:52:04.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.